Plasma contains high levels of complement and can overcome the effects of eculizumab and thereby render the patient susceptible to complications of PNH
," noted the investigators.
In particular, this news release includes forward looking information relating to a pilot proof-of-concept trial in PNH
planned by the Company, a Phase 3 clinical trial planned by the Company, research and development activities and the potential role of RVX-208 in the treatment of CVD, DM, Alzheimer's disease, peripheral artery disease, chronic kidney disease and complement mediated diseases.
is accepting toy and gift card donations at the office, located at 70 James St.
On the other hand, eculizumab treatment does not eradicate the underlying faulty PNH
clone and must be given lifelong; therefore, it is best reserved for symptomatic patients with a large percentage (more than 10%) of PNH
clones or PNH
patients with thrombosis irrespective of the size of the PNH
is an ultra-rare blood disorder that strikes people of all ages, with an average age of onset in the early 30s.
So far, we are making significant progress toward achieving our top priority of making Soliris available to every PNH
patient who can benefit from it.
The positive opinion adopted by CHMP is an important step in Alexion's mission to improve PNH
patients' lives in Europe and around the globe.
Patients with PNH
lack naturally occurring complement inhibitors which normally prevent red blood cell destruction.
APL-2 is currently being tested in a number of Phase I clinical trials and has received Orphan Drug Designation from the FDA to treat PNH
ranked #24 on the Fastest Growing Private Small Companies list in the September 2014 edition, making this the second time they have placed on this list - the first time being in 2011.
The only treatment currently available for PNH
patients is an anti-C5 antibody Soliris(TM) (eculizumab) sold by Alexion Pharmaceuticals, Inc.
This patent also comes on the heels of exciting positive results from TRIUMPH, our pivotal Phase III efficacy trial using Soliris in PNH